Safont Mireia Mayoral, Leitch Calum, Popa Mihaela, Gjerstad May Eriksen, Caulier Benjamin, Inderberg Else Marit, Wälchli Sébastien, Gelebart Pascal, McCormack Emmet
Precision Oncology Research Group, University of Bergen, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway; Kinn Therapeutics, Bergen, Norway.
Precision Oncology Research Group, University of Bergen, Bergen, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway; Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway.
STAR Protoc. 2024 Dec 20;5(4):103522. doi: 10.1016/j.xpro.2024.103522. Epub 2024 Dec 12.
Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples. Here, we present a protocol for developing a bioluminescent AML-PDX model in mice to evaluate chimeric antigen receptor (CAR) T cell therapy. We describe steps for transducing, engrafting, expanding, and enriching AML-PDX cells. We then detail procedures for in vitro and in vivo validation of the AML-PDX model for the evaluation of CAR T cell immunotherapy. For complete details on the use and execution of this protocol, please refer to Caulier et al..
急性髓系白血病患者来源的异种移植（AML-PDX）模型通过捕捉患者来源样本的复杂性和异质性，比细胞系模型具有优势。在此，我们展示了一种在小鼠中建立生物发光AML-PDX模型以评估嵌合抗原受体（CAR）T细胞疗法的方案。我们描述了转导、植入、扩增和富集AML-PDX细胞的步骤。然后，我们详细介绍了用于评估CAR T细胞免疫疗法的AML-PDX模型的体外和体内验证程序。有关本方案使用和执行的完整详细信息，请参阅Caulier等人的文章。
Zotero 插件
